Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR

Journal of Hepatology

Volumn 48, Issue 2, 2008, Pages 192-199

  Scholtes, Caroline ^a,b,c   Diaz, Olivier ^a,c   Icard, Vinca ^a,b,c   Kaul, Artur ^d   Bartenschlager, Ralf ^d   Lotteau, Vincent ^a,b   André, Patrice ^a,b,c  

^a University Lyon i   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biliary salts; Farnesoid X receptor; Guggulsterone; Hepatitis C virus; Nuclear receptors; Viral replication

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; GUGGULSTERONE; LUCIFERASE;

ARTICLE; BILE ACID BLOOD LEVEL; CONTROLLED STUDY; GENE SILENCING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REPORTER GENE; RNA REPLICATION; VIRUS REPLICATION;

EID: 37849019211     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.09.015     Document Type: Article

References (52)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
3. Jorquera F., Monte M.J., Guerra J., Sanchez-Campos S., Merayo J.A., Olcoz J.L., et al. Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol 20 (2005) 547-554
4. Lebovics E., Seif F., Kim D., Elhosseiny A., Dworkin B.M., Casellas A., et al. Pruritis in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci 42 (1997) 1094-1099
5. Kullak-Ublick G.A., Stieger B., and Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126 (2004) 322-342
6. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 284 (1999) 1362-1365
7. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999) 1365-1368
8. Goodwin B., Gauthier K.C., Umetani M., Watson M.A., Lochansky M.I., Collins J.L., et al. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 100 (2003) 223-228
9. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002) 1313-1316
10. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 65 (2003) 261-311
11. Edwards P.A., Kast H.R., and Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 43 (2002) 2-12
12. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 (1995) 687-693
13. Kalaany N.Y., and Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68 (2006) 159-191
14. Geier A., and Trautwein C. Bile acids are "homeotrophic" sensors of the functional hepatic capacity and regulate adaptive growth during liver regeneration. Hepatology 45 (2007) 251-253
15. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006) 233-236
16. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 278 (2003) 9435-9440
17. Maruyama T., Miyamoto Y., Nakamura T., Tamai Y., Okada H., Sugiyama E., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298 (2002) 714-719
18. Chang K.O., Sosnovtsev S.V., Belliot G., Kim Y., Saif L.J., and Green K.Y. Bile acids are essential for porcine enteric calicivirus replication in association with down-regulation of signal transducer and activator of transcription 1. Proc Natl Acad Sci USA 101 (2004) 8733-8738
19. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96 (1999) 12766-12771
20. Kapadia S.B., and Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102 (2005) 2561-2566
21. Ye J., Wang C., Sumpter Jr. R., Brown M.S., Goldstein J.L., and Gale Jr. M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 100 (2003) 15865-15870
22. Nakabayashi H., Taketa K., Miyano K., Yamane T., and Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42 (1982) 3858-3863
23. Quinkert D., Bartenschlager R., and Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol 79 (2005) 13594-13605
24. Lohmann V., Korner F., Dobierzewska A., and Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 75 (2001) 1437-1449
25. Krieger N., Lohmann V., and Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75 (2001) 4614-4624
26. Windisch M.P., Frese M., Kaul A., Trippler M., Lohmann V., and Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 79 (2005) 13778-13793
27. Komurian-Pradel F., Perret M., Deiman B., Sodoyer M., Lotteau V., Paranhos-Baccala G., et al. Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome. J Virol Methods 116 (2004) 103-106
28. Fischer S., Beuers U., Spengler U., Zwiebel F.M., and Koebe H.G. Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin Chim Acta 251 (1996) 173-186
29. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296 (2002) 1703-1706
30. Burris T.P., Montrose C., Houck K.A., Osborne H.E., Bocchinfuso W.P., Yaden B.C., et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 67 (2005) 948-954
31. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76 (2002) 13001-13014
32. Kato N., Sugiyama K., Namba K., Dansako H., Nakamura T., Takami M., et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem Biophys Res Commun 306 (2003) 756-766
33. Podevin P., Rosmorduc O., Conti F., Calmus Y., Meier P.J., and Poupon R. Bile acids modulate the interferon signalling pathway. Hepatology 29 (1999) 1840-1847
34. Setchell K.D., Rodrigues C.M., Clerici C., Solinas A., Morelli A., Gartung C., et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112 (1997) 226-235
35. Andre P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76 (2002) 6919-6928
36. Deforges S., Evlashev A., Perret M., Sodoyer M., Pouzol S., Scoazec J.Y., et al. Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol 85 (2004) 2515-2523
37. Diaz O., Delers F., Maynard M., Demignot S., Zoulim F., Chambaz J., et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 87 (2006) 2983-2991
38. Miyamoto M., Kato T., Date T., Mizokami M., and Wakita T. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology 49 (2006) 37-43
39. Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J., et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 64 (2001) 334-339
40. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103 (2006) 7408-7413
41. Binder M., Quinkert D., Bochkarova O., Klein R., Kezmic N., Bartenschlager R., et al. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 81 (2007) 5270-5283
42. Guo J.T., Bichko V.V., and Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 75 (2001) 8516-8523
43. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., and Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 75 (2001) 1252-1264
44. Li T., Jahan A., and Chiang J.Y. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 43 (2006) 1202-1210
45. Aizaki H., Lee K.-J., Sung V.M.-H., Ishiko H., and Lai M.M.C. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324 (2004) 450-461
46. Rakic B., Sagan S.M., Noestheden M., Belanger S., Nan X., Evans C.L., et al. Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. Chem Biol 13 (2006) 23-30
47. Dharancy S., Malapel M., Perlemuter G., Roskams T., Cheng Y., Dubuquoy L., et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128 (2005) 334-342
48. Kim K.H., Hong S.P., Kim K., Park M.J., Kim K.J., and Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 355 (2007) 883-888
49. Waris G., Felmlee D.J., Negro F., and Siddiqui A. Hepatitis C virus induces the proteolytic cleavage of sterol regulatory element binding proteins (SREBPs) and stimulates the phosphorylation of SREBPs via oxidative stress. J Virol 81 (2007) 8122-8130
50. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113 (2004) 1408-1418
51. Duran-Sandoval D., Cariou B., Fruchart J.C., and Staels B. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87 (2005) 93-98
52. Cariou B., and Staels B. FXR: a promising target for the metabolic syndrome?. Trends Pharmacol Sci 28 (2007) 236-243